{"filings":[{"id":1027322,"accession_number":"0001104659-26-073431","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2026-06-12T20:06:12+00:00","items":["5.02","5.07"],"status":"ready","headline":"Sagimet director Tim Walbert resigns; annual meeting ratifies board and auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Tim Walbert resigned from Board effective June 12, 2026, citing other commitments, no disagreement.","All four Class III directors elected: Jarrett, Phillips, Happel, Kemble with 6.5M-8.8M votes for each.","KPMG LLP ratified as independent auditor for FY 2026: 19.1M for, 14k against.","Outstanding shares of Series A common stock: 32,017,613 as of record date April 17, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":834642,"accession_number":"0001104659-26-070126","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2026-06-03T20:30:38+00:00","items":["5.02","9.01"],"status":"ready","headline":"Sagimet awards 450k options and 450k PSUs to CEO, CFO, and Chief Legal Officer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO David Happel receives 300,000 options and 300,000 PSUs at $7.27 exercise price.","CFO Thierry Chauche receives 50,000 options and 50,000 PSUs; Chief Legal Officer Elizabeth Rozek receives 100,000 each.","Options vest over 48 months; PSUs tied to regulatory milestones with one-third cliff vest at achievement date.","PSU award form filed as Exhibit 10.1; grants under 2023 Stock Option and Incentive Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":22524,"accession_number":"0001104659-26-059009","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2026-05-12T11:35:31+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sagimet Q1 net loss $10.7M; $175M April financing; Phase 3 acne trial H2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $10.7M for Q1 2026 vs $18.2M in Q1 2025; R&D expense $7.0M (down from $15.3M YoY).","Cash, cash equivalents and marketable securities $104.5M as of March 31, 2026; expects funding through 2028.","Completed $175M equity financing in April 2026 (29.2M shares at $6.00) to fund acne programs.","Plans to initiate U.S. Phase 3 trial of denifanstat in moderate-to-severe acne in second half 2026.","Phase 1 trial of FASN inhibitor TVB-3567 ongoing; Phase 2 planned after completion subject to regulatory consultation."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92631,"accession_number":"0001104659-26-049756","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Sagimet Biosciences prices public offering of 29.2M shares at $6.00/share for ~$164.5M net proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 29,166,700 shares of common stock at $6.00 per share; net proceeds expected $164.5 million.","Net proceeds to fund Phase 3 trial of denifanstat in acne, TVB-3567 through Phase 2, and topical FASN inhibitor to IND.","Joint book-running managers: Leerink Partners, TD Securities, Guggenheim Securities, and Oppenheimer & Co.","Co-lead managers: Canaccord Genuity, H.C. Wainwright, and JonesTrading."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92630,"accession_number":"0001104659-26-049015","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sagimet updates investor presentation; no specifics disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed Item 7.01 with investor presentation dated April 2026.","No financial or clinical data detailed in the filing or exhibit excerpt.","Presentation slides not reproduced; materiality cannot be assessed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92629,"accession_number":"0001104659-26-048971","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Sagimet pivots to acne, pauses MASH; cash $104.5M; Phase 3 acne trial H2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash balance $104.5M as of Mar 31, 2026; provides runway for strategic pivot.","Phase 3 U.S. trial of denifanstat in moderate-to-severe acne planned for H2 2026, pending IND clearance.","MASH development paused until non-dilutive funding secured; combination program with resmetirom ready for Phase 2.","New CMO Andreas Grauer appointed; Phase 1 of TVB-3567 ongoing, Phase 2 acne trial targeted for H2 2026.","Positive Phase 3 acne safety results from partner Ascletis in China reported Jan 2026 (n=240)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92628,"accession_number":"0001104659-26-045629","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Sagimet Biosciences CMO Eduardo Martins retires; Andreas Grauer appointed as replacement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CMO Eduardo Martins retired effective April 20, 2026; will remain as external scientific advisor.","Andreas Grauer, M.D., appointed as new CMO, effective April 20, 2026.","Dr. Grauer previously served as CMO at Omeros Corporation (Oct 2023–Apr 2026) and earlier at Federation Bio, Corcept, Amgen.","He also serves as Associate Professor of Medicine at University of Heidelberg Medical School."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103600,"accession_number":"0001104659-26-026146","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Sagimet Biosciences Reports 2025 Financial Results and MASH/Acne Program Updates","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and marketable securities $113.1M; net loss $51M for full year 2025.","Completed Phase 1 PK trial of denifanstat+resmetirom; Phase 2 combo trial in F4 MASH expected 2H 2026.","Exclusive license from TAPI for innovative resmetirom API forms to develop fixed-dose combination.","Ascletis reported positive Phase 3 acne data for denifanstat; NDA accepted by China NMPA.","Initiated Phase 1 trial of TVB-3567, a FASN inhibitor for acne."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103599,"accession_number":"0001104659-26-008925","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2026-02-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sagimet's partner Ascletis reports positive Phase 3 open-label 52-week acne data for denifanstat","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["240 subjects received oral denifanstat 50 mg once daily for up to 40 weeks; 52 weeks total for prior denifanstat patients.","Denifanstat well tolerated: dry eye syndrome (5.5%) and dry skin (5.2%) most common TEAEs; no denifanstat-related SAEs.","No AE-related discontinuations; only 1 grade 1 hair thinning resolved without dose change; no deaths.","All efficacy endpoints (IGA, lesion counts) showed improvements beyond those seen at 12 weeks in the prior Phase 3 trial.","Ascletis holds China rights; Sagimet retains ex-China rights for denifanstat (FASN inhibitor)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119865,"accession_number":"0001104659-25-122272","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Sagimet announces positive Phase 1 PK data for denifanstat/resmetirom combo in MASH","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 PK trial (NCT07216313) of denifanstat + resmetirom in 40 healthy adults met objectives; combination well-tolerated, no SAEs.","PK data support further development; no drug-drug interaction signals observed; no treatment discontinuations.","Company plans Phase 2 proof-of-concept trial in MASH F4 fibrosis patients in 2H 2026 pending regulatory consultation.","Global license agreement with TAPI (TEVA affiliate) to develop once-daily fixed-dose combination tablet for Phase 3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119864,"accession_number":"0001104659-25-121819","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Sagimet enters global exclusive license with TAPI for innovative resmetirom API for FDC program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["License grants Sagimet exclusive global rights to TAPI's innovative forms of resmetirom API for fixed-dose combination with denifanstat.","Sagimet paid $2.5M upfront; TAPI may receive low single-digit royalties and up to $5.5M in manufacturing milestones.","Phase 1 PK trial of denifanstat + resmetirom underway; topline data expected by end of 2025.","Sagimet plans to select one TAPI resmetirom form for a single FDC tablet for Phase 3 study in H2 2026.","Combination targets MASH cirrhosis (F4) where no approved therapies exist."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119863,"accession_number":"0001104659-25-110852","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Sagimet reports Q3 2025 net loss $12.9M; advances denifanstat + resmetirom combo trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q3 2025 was $12.9M vs $14.6M YoY; nine-month net loss $41.5M vs $29.4M.","Cash, cash equivalents and marketable securities totaled $125.5M as of Sept 30, 2025.","Phase 1 PK trial of denifanstat plus resmetirom in MASH cirrhosis underway; data expected 1H 2026.","Partner Ascletis completed pre-NDA consultation with China NMPA for denifanstat in acne vulgaris; NDA submission planned.","Marie O'Farrell promoted to CSO and Liz Rozek to Chief Legal & Admin Officer effective Nov 1, 2025."],"consensus_eps_estimate":-0.3933,"consensus_eps_actual":-1.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119862,"accession_number":"0001104659-25-101819","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2025-10-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sagimet updates investor presentation highlighting MASH, acne, and cancer pipeline","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation dated October 23, 2025, targets metabolic dysfunction with novel therapies for MASH, acne, and cancer.","Management will use the updated deck in investor meetings; specific data or milestones not disclosed in filing excerpt.","No financial results, guidance changes, or clinical trial readouts included in the furnished exhibit (title page only)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136429,"accession_number":"0001104659-25-081630","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2025-08-22T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Sagimet appoints KPMG as auditor, dismisses Deloitte; no disagreements reported","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Audit Committee and Board approved KPMG as independent auditor for FY 2025 and dismissed Deloitte effective August 18, 2025.","Deloitte's audit reports for 2023 and 2024 contained no adverse opinion or qualification.","No disagreements with Deloitte occurred in the past two fiscal years or interim period through August 18, 2025.","KPMG had not been previously consulted on accounting principles or audits prior to engagement.","Deloitte provided a letter agreeing with disclosure, attached as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136428,"accession_number":"0001104659-25-078752","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Sagimet Biosciences enters $75M ATM equity facility with Leerink Partners, terminates prior Cantor facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $75M in common stock may be sold from time to time via at-the-market offerings through Leerink Partners.","Agent commission of up to 3.0% on gross proceeds from sales under the agreement.","Prior Cantor Fitzgerald ATM agreement terminated effective Aug 14, 2025; no shares were sold under that facility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136427,"accession_number":"0001104659-25-077200","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Sagimet Q2 net loss $10.4M, cash $135.5M; denifanstat meets all acne Phase 3 endpoints","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q2 2025 $10.4M vs $8.1M; H1 loss $28.6M vs $14.7M; R&D and G&A both increased.","Cash position $135.5M at June 30, 2025; no revenue reported (pre-revenue biotech).","Denifanstat Phase 3 acne trial (Ascletis) met all endpoints: treatment success 33.2% vs 14.6% (p<0.0001).","Initiated Phase 1 for TVB-3567 (acne) in U.S.; combo trial denifanstat+resmetirom PK study planned 2H 2025 with readout 1H 2026."],"consensus_eps_estimate":-0.5176,"consensus_eps_actual":-0.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153579,"accession_number":"0001104659-25-058201","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2025-06-10T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Sagimet amends executive severance agreements with CEO, CFO, and NEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO David Happel gets 24 months base salary, target bonus, equity acceleration on change-in-control termination.","CFO Thierry Chauche and NEO Eduardo Martins get 15 months severance under same conditions.","Annual meeting elected Elizabeth Grammer and Beth Seidenberg as Class II directors; ratified Deloitte & Touche as auditor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153578,"accession_number":"0001104659-25-056160","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sagimet partner Ascletis reports positive Phase 3 acne results for denifanstat; Sagimet starts Phase 1 of TVB-3567","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Denifanstat (50mg once daily) met all primary and secondary endpoints vs placebo in Phase 3 acne trial (n=480) in China.","Treatment success (IGA) 33.2% denifanstat vs 14.6% placebo (p<0.0001); total lesion count change −57.4% vs −35.4%.","Denifanstat well-tolerated; TEAEs comparable to placebo, only dry skin (6.3%) and dry eye (5.9%) above 5%.","Ascletis plans to submit denifanstat for approval to China's NMPA; Sagimet initiated Phase 1 of TVB-3567 for US acne.","Oral FASN inhibition offers novel mechanism for moderate-to-severe acne, a condition affecting 640M+ globally."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153577,"accession_number":"0001104659-25-045791","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Sagimet Biosciences reports Q1 net loss of $18.2M; plans Phase 1 combo trial with resmetirom in 2H 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net loss $18.2M (vs $6.6M Q1 2024); R&D expense $15.3M (vs $5.3M). Cash $144.6M.","Phase 1 PK trial of denifanstat + resmetirom expected to start 2H 2025; data readout 1H 2026.","End-of-Phase 2 FDA interaction completed Oct 2024; Phase 3 deferred until sufficient funding secured.","Board changes: George Kemble to non-executive Chair; Beth Seidenberg appointed Lead Independent Director; Merdad Parsey to step off June 9, 2025.","License partner Ascletis completed enrollment of 480-patient Phase 3 acne trial in China; topline results expected Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153576,"accession_number":"0001104659-25-042566","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sagimet Biosciences director Merdad Parsey will not stand for re-election at 2025 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Merdad Parsey, M.D., Ph.D., notified Board on April 29, 2025 he will not seek re-election at the 2025 Annual Meeting scheduled June 9, 2025.","Dr. Parsey will continue as director until the Annual Meeting; departure not due to any disagreement with the Company.","No successor or replacement was announced; board size and composition implications unclear."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172292,"accession_number":"0001104659-25-022763","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Sagimet reports FY2024 net loss of $45.6M; advances denifanstat Phase 3 in MASH and TVB-3567 IND clearance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2024 net loss $45.6M ($27.9M in 2023); R&D expense $38.4M, up from $19.8M.","Cash $158.7M at Dec 31, 2024; funded by Jan 2024 follow-on offering of 9M shares netting $104.7M.","Phase 3 denifanstat program for MASH initiated; patient screening expected 1H 2025; includes FASCINATE-3 and FASCINIT.","FDA granted Breakthrough Therapy designation for denifanstat in non-cirrhotic MASH with F2/F3 fibrosis.","IND cleared for TVB-3567, a second FASN inhibitor for acne; Phase 1 trial planned in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172291,"accession_number":"0001104659-25-022423","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Sagimet's second FASN inhibitor TVB-3567 gets IND clearance for acne","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA's Division of Dermatology and Dentistry cleared IND for TVB-3567, a small molecule FASN inhibitor.","TVB-3567 targets sebum production; FASN drives ~80% of sebum lipids in acne pathogenesis.","First-in-human Phase 1 trial planned for 2025, randomized, double-blind, placebo-controlled.","Building on denifanstat data, partner Ascletis showed significant lesion reduction in Phase 2 acne trial.","Over 50 million acne patients in the US; FASN inhibition seen as significant commercial opportunity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172290,"accession_number":"0001104659-25-014099","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Sagimet files updated investor presentation; no specific material changes disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed an updated slide presentation dated February 14, 2025, for use in investor meetings.","Presentation title: 'Targeting Metabolic Dysfunction with Novel Therapies to Treat MASH, Acne & Cancer'.","No financial results, guidance changes, or material events are reported in the filing or exhibit excerpt.","The 8-K is a routine update under Item 8.01 with no detailed new information provided.","Confidence is low because the full presentation slides are not visible in the filing text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172289,"accession_number":"0001104659-25-000137","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2025-01-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Sagimet issues updated January 2025 investor slide deck on MASH, acne, and cancer pipeline","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Updated slide presentation dated January 2025 addresses metabolic dysfunction therapies for MASH, acne, and oncology.","Presentation will be used in investor meetings; no financial results or clinical milestones disclosed in the filing.","No specific data, guidance, or material events announced; update appears to be routine corporate presentation refresh."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189284,"accession_number":"0001104659-24-118342","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sagimet Q3 2024 net loss $14.6M; cash $170M; denifanstat Phase 3 start expected by end of 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $14.6M for Q3 2024, vs $6.4M in Q3 2023; R&D expense increased to $12.7M.","Cash, equivalents and marketable securities of $170.0M as of Sept 30, 2024; expected to fund operations through 2025.","Denifanstat received FDA Breakthrough Therapy designation for non-cirrhotic MASH (F2/F3 fibrosis); Phase 3 program expected to initiate by end of 2024.","Phase 2b FASCINATE-2 results published in The Lancet Gastroenterology & Hepatology; end-of-Phase 2 interactions completed.","License partner Ascletis completed enrollment of 480 patients in Phase 3 acne trial in China; topline results expected Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205785,"accession_number":"0001104659-24-090546","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2024-08-16T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Sagimet Biosciences enters into $75M ATM equity sales agreement with Cantor Fitzgerald","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Controlled Equity Offering Sales Agreement with Cantor Fitzgerald dated August 15, 2024.","Company may sell up to $75M of Series A common stock through at-the-market offerings.","Agent entitled to commission of up to 3% of gross proceeds from each sale.","Company has no obligation to sell shares and may suspend or terminate at any time.","Registration statement on Form S-3 filed same day; sales only after SEC declares effective."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205784,"accession_number":"0001104659-24-089340","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Sagimet Q2 net loss $8.1M, cash $188.5M; denifanstat fibrosis data positive; Phase 3 plan H2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and marketable securities $188.5M as of June 30, 2024; net loss $8.1M for Q2 2024 vs $6.8M year ago.","Denifanstat Phase 2b: fibrosis improvement ≥1 stage in 30% vs 14% placebo (ITT); 49% vs 13% in F3 patients.","Anne Phillips and Jennifer Jarrett appointed to board effective August 1, 2024.","Phase 3 program for denifanstat in MASH expected to start H2 2024; CRO contract executed.","R&D expense $6.3M and G&A $4.3M in Q2 2024, up from $4.7M and $2.4M year ago."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205783,"accession_number":"0001104659-24-084645","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sagimet Biosciences expands board to 9, appoints Jennifer Jarrett and Dr. Anne Phillips as directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 7 to 9 directors; appointments effective August 1, 2024.","Jennifer Jarrett, COO of Arcus Biosciences, joins Audit Committee; Dr. Anne Phillips, former Novo Nordisk SVP, joins Nominating & Governance Committee.","Each new director receives initial stock option grant of $300,000 vesting over 3 years under 2023 Stock Option Plan.","Both are independent under Nasdaq rules; no related party transactions disclosed.","Jarrett serves on boards of Syndax, Zura Bio, others; Phillips on boards of Trevena, Barinthus, vTv Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205782,"accession_number":"0001104659-24-077430","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2024-07-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Sagimet updates investor presentation; no material financial or clinical data changes","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company filed updated slide presentation for investor meetings dated July 2, 2024.","Presentation covers pipeline programs in MASH, acne, and cancer.","No specific new results, guidance, or material developments were disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222741,"accession_number":"0001104659-24-071014","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K/A","filed_at":"2024-06-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Sagimet reports positive Phase 2b MASH data for denifanstat; primary endpoints met","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoints achieved: ≥2-point NAS reduction without fibrosis worsening (38% vs 16%, p=0.0035) and MASH resolution (26% vs 11%, p=0.0173) in ITT.","Fibrosis improvement ≥1 stage without MASH worsening: ITT 30% vs 14% (p=0.0199); F3 subgroup 49% vs 13% (p=0.0032).","Fibrosis improvement ≥2 stages: mITT 20% vs 2% (p=0.0065); F3 34% vs 4% (p=0.0050).","No treatment-related SAEs; discontinuation rate 19.6% denifanstat vs 5.4% placebo.","Company plans to initiate Phase 3 registrational program for denifanstat in MASH in H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222745,"accession_number":"0001104659-24-068817","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"Sagimet reports positive FASCINATE-2 Phase 2b data; denifanstat meets primary endpoints in MASH","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint: MASH resolution with ≥2-point NAS reduction without worsening fibrosis: 38% denifanstat vs 16% placebo (p=0.0035) in ITT.","Fibrosis improvement ≥1 stage without worsening MASH: 30% vs 14% placebo (p=0.0199) in ITT; 49% vs 13% in F3 subgroup (p=0.0032).","Fibrosis improvement ≥2 stages in mITT: 20% vs 2% placebo (p=0.0065); 34% vs 4% in F3 subgroup (p=0.0050).","No treatment-related SAEs; most AEs mild/moderate. TEAE discontinuation 19.6% denifanstat vs 5.4% placebo.","Company plans to initiate Phase 3 registrational program for denifanstat in MASH with fibrosis in H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222744,"accession_number":"0001104659-24-064509","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sagimet Biosciences updates investor presentation; no new material data disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed an updated slide presentation as Exhibit 99.1 under Item 7.01 Regulation FD Disclosure.","Presentation titled 'Targeting Metabolic Dysfunction with Novel Therapies to Treat MASH, Acne and Cancer' dated May 2024.","No specific financial or clinical data from the presentation were provided in the filing text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222743,"accession_number":"0001104659-24-061609","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sagimet Q1 2024 net loss $6.6M; cash $193.7M; FDA End-of-Phase 2 meeting in Q2; MASH Phase 3 start H2","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q1 2024 was $6.6M, flat year-over-year; R&D expense $5.3M, G&A $3.5M.","Cash, cash equivalents and marketable securities total $193.7M as of March 31, 2024, expected to fund operations through 2025.","Denifanstat Phase 2b FASCINATE-2 full data to be presented as oral at EASL June 5-8, 2024.","End-of-Phase 2 meeting with FDA anticipated in Q2 2024; Phase 3 trial start planned for second half of 2024.","Follow-on offering in January 2024 netted $104.7M to support pipeline and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222742,"accession_number":"0001104659-24-057228","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sagimet Biosciences appoints Thierry Chauche as CFO, effective May 6, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Thierry Chauche named CFO, replacing interim CFO Joseph Oriti who resigned.","Chauche receives $480k base salary, 40% target bonus, and option grant valued at $2M (Black-Scholes).","Option vests over 4 years (25% cliff at 1 year, then monthly).","Severance: 6 months base salary (12 months during change in control), plus COBRA and equity acceleration.","Chauche previously CFO of Provention Bio and held roles at Alexion, Intercept, Novartis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242232,"accession_number":"0001104659-24-038101","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2024-03-25T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Sagimet FY2023 net loss $27.9M; denifanstat Phase 2b hits endpoints; board adds Walbert, Hoelscher","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $27.9M for FY2023 vs $30.5M in 2022; revenue $2.0M from milestone payment.","Cash, equivalents and securities $94.9M at Dec 31, 2023; Jan 2024 offering added $104.7M net.","Denifanstat Phase 2b FASCINATE-2 met primary endpoints: MASH resolution 36% vs 13% (p=0.0022); fibrosis improvement 41% vs 18% (p=0.005).","Board expanded from 7 to 9 directors; Tim Walbert (ex-Horizon CEO) and Paul Hoelscher (ex-Horizon CFO) appointed eff. April 1, 2024.","Directors Richard Rodgers and Jinzi Wu will not stand for re-election at June 2024 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242231,"accession_number":"0001104659-24-010085","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2024-02-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sagimet CFO Rimac resigns; Oriti appointed interim CFO & PFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Anthony Rimac resigned as CFO effective January 31, 2024; previously disclosed.","Joseph Oriti appointed Interim Principal Financial Officer and Principal Accounting Officer effective February 1, 2024.","Oriti, a director at Stout Risius Ross, will serve as consultant; no family or arrangement disclosures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242230,"accession_number":"0001104659-24-008230","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2024-01-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Sagimet Biosciences prices public offering of 9M shares at $12.50/share, raising $112.5M gross","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 9,000,000 shares of Series A common stock at $12.50/share; gross proceeds ~$112.5M before expenses.","Underwriters granted 30-day option to purchase up to 1,350,000 additional shares at the offering price.","Net proceeds to fund denifanstat Phase 3 program in NASH, TVB-3567 IND for acne, and general corporate.","Offering closed January 30, 2024; Goldman Sachs, TD Cowen, and Leerink acted as joint book-running managers.","All shares sold by Sagimet; no selling stockholders in the offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242229,"accession_number":"0001104659-24-006042","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2024-01-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sagimet Biosciences reports preliminary cash of $94.9M as of Dec 31, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, cash equivalents and short-term investments estimated at ~$94.9M.","Amount is unaudited, prepared by management and subject to completion of closing procedures.","Actual year-end 2023 results may differ; will be included in Form 10-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242228,"accession_number":"0001104659-24-005399","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2024-01-22T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Sagimet reports positive Phase 2b NASH trial: denifanstat meets primary endpoints with statistical significance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NASH resolution without worsening fibrosis (≥2-point NAS reduction): 36% denifanstat vs 13% placebo (p=0.0022).","Fibrosis improvement ≥1 stage without NASH worsening: 41% denifanstat vs 18% placebo (p=0.0051).","MRI-PDFF ≥30% reduction: 65% denifanstat vs 21% placebo (p<0.0001).","No treatment-related SAEs; discontinuation rate 19.6% denifanstat vs 5.4% placebo."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259638,"accession_number":"0001104659-23-130486","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2023-12-29T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"CFO Anthony Rimac to resign Jan. 31, 2024; interim appointments from Stout","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Anthony Rimac resigns effective Jan. 31, 2024 for personal reasons; no disagreement with company or auditors.","Stout's Gaeton Biscardi named Interim VP of Finance; Joe Oriti to serve as consultant and likely Interim Principal Financial Officer.","Board intends to appoint Oriti as Interim PFO and will conduct a search for a permanent CFO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259637,"accession_number":"0001104659-23-120365","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2023-11-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sagimet Biosciences grants RSUs to executives post-IPO; CEO Happel receives 624,910 units","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved RSU grants: CEO David Happel (624,910), Eduardo Martins (89,570), George Kemble (150,750).","RSUs vest 25% on first anniversary of IPO closing, remainder over three years, subject to continued service.","Compensation Committee engaged Compensia to align executive compensation with public-company peers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259636,"accession_number":"0001104659-23-116795","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sagimet reports Q3 net loss of $6.4M; cash $101.8M; NASH data due Q1 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $6.4M vs $7.5M in Q3 2022; revenue $2.0M from milestone vs zero year-ago.","Cash $101.8M, expected to fund operations at least 12 months.","Phase 2b FASCINATE-2 (denifanstat) week 52 liver biopsy results expected Q1 2024.","Two AASLD abstracts accepted; preclinical FASN inhibitor + semaglutide combo data shown.","Ascletis enrolled 120 patients in Phase 3 denifanstat + bevacizumab for recurrent GBM."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":2000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259635,"accession_number":"0001104659-23-110654","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2023-10-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sagimet furnishes updated investor presentation on NASH, acne, cancer pipeline","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed updated slide deck under Item 7.01 for use in investor meetings.","Presentation targets metabolic dysfunction therapies for NASH, acne, and cancer.","No specific financial or clinical data from the deck was disclosed in the 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276901,"accession_number":"0001104659-23-104304","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2023-09-27T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Sagimet partner Ascletis enrolls 120 patients in Phase 3 trial of denifanstat for rGBM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ascletis completed enrollment of 120 patients in Phase 3 registration trial of denifanstat plus bevacizumab for recurrent glioblastoma.","Interim analysis of progression-free survival anticipated after sufficient events from the 120 subjects.","Sagimet expects FASCINATE-2 Phase 2b NASH biopsy results and Phase 1 hepatic impairment data in Q1 2024.","Denifanstat is an oral FASN inhibitor; Sagimet licensed China rights to Ascletis in January 2019."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276900,"accession_number":"0001104659-23-093921","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2023-08-21T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Sagimet Q2 net loss $6.8M; IPO raised $86.2M net; denifanstat 67% fat reduction","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["IPO closed July 18: 6,026,772 shares at $16; gross proceeds $96.4M, net $86.2M.","Cash $18.5M at June 30; combined with IPO proceeds extends runway into Q1 2025.","Phase 2b FASCINATE-2 interim: 67% denifanstat achieved ≥30% liver fat reduction vs 18% placebo (p<0.001).","Tony Rimac appointed CFO (previously COO) after Dennis Hom departure; Liz Rozek as General Counsel & CCO.","Net loss $13.4M for H1 2023; R&D $9.2M, G&A $4.7M; no FY2023 guidance provided."],"consensus_eps_estimate":null,"consensus_eps_actual":-71.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":2000000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276899,"accession_number":"0001104659-23-089579","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sagimet posts updated investor presentation on NASH, acne, cancer pipeline","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company furnished investor slide deck dated August 10, 2023; no financial results disclosed.","Presentation focuses on novel therapies targeting metabolic dysfunction for NASH, acne, and cancer.","No quantitative updates (e.g., clinical data, revenue, guidance) provided in filing or exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276898,"accession_number":"0001104659-23-084764","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2023-07-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sagimet Biosciences names Anthony Rimac CFO effective August 1, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Anthony Rimac appointed CFO, principal financial and accounting officer, effective Aug 1, 2023.","Rimac has served as COO since April 2023 and will retain that role.","Board has not yet determined any compensation changes related to CFO appointment.","No family relationships with existing directors/officers; no related party transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276897,"accession_number":"0001104659-23-082006","cik":1400118,"company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","form_type":"8-K","filed_at":"2023-07-18T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Sagimet Biosciences closes IPO; files amended charter and bylaws effective July 18, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized 500M shares of Series A common stock and 15M shares of Series B common stock.","Reclassified outstanding common stock as Series A common stock upon IPO closing.","Charter authorizes 10M shares of undesignated preferred stock issuable in series by Board.","Bylaws eliminate stockholder action by written consent and set procedures for proposals and director nominations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":457658632.3767314,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}